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Abstract Cytochrome P450 (CYP) 1A1 is the most
important enzyme activating and detoxifying the human
carcinogen benzo[a]pyrene (BaP). In the previous studies,
we had shown that not only the canonic NADPH:CYP
oxidoreductase (POR) can act as electron donor but also
cytochrome b5 and its reductase, NADH:cytochrome b5
reductase. Here, we studied the role of the expression
system used on the metabolites generated and the levels of
DNA adducts formed by activated BaP. We used an
eukaryotic and a prokaryotic cellular system (Supersomes,
microsomes isolated from insect cells, and Bactosomes, a
membrane fraction of Escherichia coli, each transfected
with cDNA of human CYP1A1 and POR). These were
reconstituted with cytochrome b5 with and without
NADH:cytochrome b5 reductase. We evaluated the effec-
tiveness of each cofactor, NADPH and NADH, to mediate
BaP metabolism. We found that both systems differ in
catalysing the reactions activating and detoxifying BaP.
Two BaP-derived DNA adducts were generated by the
CYP1A1-Supersomes, both in the presence of NADPH and
NADH, whereas NADPH but not NADH was able to
support this reaction in the CYP1A1-Bactosomes. Seven
BaP metabolites were found in Supersomes with NADPH
or NADH, whereas NADPH but not NADH was able to
generate five BaP metabolites in Bactosomes. Our study
demonstrates different catalytic efficiencies of CYP1A1
expressed in prokaryotic and eukaryotic cells in BaP
bioactivation indicating some limitations in the use of
E. coli cells for such studies.
Graphical abstract
Keywords DNA  Enzymes  Coenzymes  Membranes 
Proteins
Introduction
Benzo[a]pyrene (BaP) (Fig. 1) is a polycyclic aromatic
hydrocarbon (PAH), which has been classified as human
carcinogen (Group 1) by the International Agency for
Research on Cancer [1]. In addition to the amount ingested,
the activation of BaP is crucial for its carcinogenic potential
[2]. BaP activation is catalysed by cytochrome P450 (CYP)
enzymes, but it is also detoxified by these enzymes to
metabolites that are excreted [3]. CYP1A1was found to be the
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CYP primarily involved in the metabolic activation of BaP to
species forming DNA adducts [3–6]. CYP1A1 oxidises BaP
to an epoxide that is then converted to BaP-7,8-dihydrodiol by
microsomal epoxide hydrolase (EH). Further bioactivation by
CYP1A1 leads to the ultimate reactive species, BaP-7,8-di-
hydrodiol-9,10-epoxide (BPDE) that can react with DNA,
forming adducts preferentially at guanine residues (Fig. 1).
The 10-(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-7,8,9,10-te-
trahydro-BaP (dG-N2-BPDE) adduct (Fig. 1) is the major
product of the reaction ofBPDEwithDNA invitro and in vivo
[4, 5, 7–11].
CYP1A1, however, is also responsible for BaP detoxi-
fication; BaP-dihydrodiols, BaP-diones, and hydroxylated
BaP, some of which are excreted [3, 9, 13–16]. One of
these metabolites, 9-hydroxy-BaP (BaP-9-ol), is formed
predominantly by CYP1A1 and is a precursor of 9-hy-
droxy-BaP-4,5-epoxide, which can also form an adduct
with deoxyguanosine in DNA (Fig. 1) [4, 5, 10, 11, 17–19].
Many other CYP enzymes, CYP1B1, 2B6, 2C8, 2C9,
2C19, and 3A4, have all been reported to oxidise BaP, but
their efficiencies are about one order of magnitude lower
than CYP1A1 [3, 9, 14, 20]. However, several studies have
reported controversial results on the potency of CYP1A1 as
well as other CYP enzymes to oxidise BaP
[3, 6, 9, 14, 15, 21–30]. The reasons for these discrepancies
are still a matter of debate and remain to be explored.
CYP enzymes are a component of the monooxygenase
system located in the membrane of the endoplasmic
reticulum (microsomes). CYPs function by catalysing the
insertion of one atom of molecular oxygen into a variety of
xenobiotics, including BaP, while reducing the other oxy-
gen atom to water, a reaction that requires two electrons
[31]. These are classically supplied by NADPH:CYP oxi-
doreductase (POR) [31]. Early studies with reconstituted
rat CYPs had, however, indicated a role for cytochrome b5
in NADH-dependent hydroxylation of BaP [21, 22]. We
and others have since shown that the second electron
needed for the reduction of CYPs may also be provided by
cytochrome b5 which may be reduced by POR and NADPH
or by NADH:cytochrome b5 reductase (Fig. 2) [28, 31–36].
Moreover, recently, we have demonstrated that the
NADH:cytochrome b5 reductase/cytochrome b5 system can
even act as sole electron donor for both reduction steps in
the CYP1A1-reaction cycle catalysing the oxidation of BaP
[4, 5]. Therefore, the levels of individual enzyme compo-
nents and amounts relative to the CYP1A1 monooxygenase
Fig. 1 Proposed pathways of biotransformation and DNA adduct
formation of BaP catalysed by CYP1A1 and EH. The typical three-
step activation process by CYP1A1 followed by hydrolysis by EH
leads to BPDE which forms dG-N2-BPDE (adduct 1) and the two-step
activation process by CYP1A1 leads to the formation of 9-hydroxy-
BaP-4,5-epoxide that can react with deoxyguanosine in DNA (adduct
2) are shown in yellow. Formation of detoxification metabolites is
shown in green. Insert: Structure of human CYP1A1 protein in a
complex with a-naphthoflavone [12]
M. Stiborova´ et al.
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systems can dramatically influence CYP efficiencies to
oxidise BaP.
Several systems containing CYP, such as hepatocytes,
hepatic microsomes, purified CYP enzymes reconstituted
with POR or NADH:cytochrome b5 reductase and cyto-
chrome b5 with or without EH in liposomes, and/or
recombinant CYP enzymes expressed in various cellular
expression systems, have been utilised to study the meta-
bolism of xenobiotics, including BaP in vitro (see
[4, 5, 19–30, 36–41]). For reasons not yet unravelled, the
yield in BaP metabolites and their pattern vary on the
system studied. The present study was performed to follow
up our previous work, where we showed that the
NADH:cytochrome b5 reductase/cytochrome b5 system
[4, 5] can act as sole electron donor in CYP1A1 catalysed
BaP oxidation in Supersomes. In those studies, the results
in liposomes reconstituted with isolated CYP1A1,
NADH:cytochrome b5 reductase/cytochrome b5 with or
without POR were, however, not the same as in Super-
somes, which express CYP1A1 and POR and were
reconstituted with cytochrome b5. In the present study, we
used a third defined in vitro system, namely, a membrane
fraction isolated from Escherichia coli transfected with
human CYP1A1 and POR (Bactosomes). These were
reconstituted with NADH:cytochrome b5 reductase/cy-
tochrome b5 system. The role of NADH:cytochrome b5
reductase/cytochrome b5 in BaP metabolism by CYP1A1
in these distinct environments was studied.
Results and discussion
Oxidation of BaP by human CYP1A1 expressed
in Supersomes and Bactosomes in the presence
of NADPH or NADH
We compared the oxidation of BaP by two enzymatic
systems containing human recombinant CYP1A1, namely,
eukaryotic Supersomes and prokaryotic Bactosomes.
Because Supersomes are microsomes (particles of broken
endoplasmic reticulum), other enzymes of the endoplasmic
reticulum membrane (i.e., NADH:cytochrome b5 reduc-
tase, EH, and cytochrome b5) are also expressed at basal
levels as declared by the supplier (Gentest Corp., Woburn,
MI, USA) [4]. The second experimental system we used
was Bactosomes the membrane fraction of E. coli
(prokaryotic) cells, in which human CYP1A1 and POR are
over-expressed (Cypex, BioDundee, Dundee, UK). This
system has been found to catalyse the CYP-mediated
metabolism of various xenobiotics [42–45].
To confirm the presence of enzymes essential for the
conversion of BaP in each CYP1A1 system, their expres-
sion was analysed by Western blotting using antibodies
against the mammalian proteins (Fig. 3).
Figure 3 shows that similar levels of human CYP1A1
were over-expressed in Supersomes and Bactosomes, while
the amount of POR was higher in Supersomes than in
Bactosomes. Because BaP is also a substrate for CYP1B1
[14, 20], its expression was also analysed. Interestingly,
employing the anti-human CYP1B1 antibody, CYP1B1
was detectable in Supersomes at basal levels (in amounts
much lower than CYP1A1). In contrast, its expression was
essentially not detectable in Bactosomes, as expected, since
these are prokaryotic membranes. Cytochrome b5 and its
reductase, NADH:cytochrome b5 reductase, were
detectable in both systems, but levels were much lower
than those of POR. Expression levels of EH were close to
the detection limit of the Western blot method.
To examine whether indeed cytochrome b5 can act as
sole electron donor in CYP1A1-catalysed BaP oxidation in
both membrane systems, Supersomes and Bactosomes
were reconstituted with isolated cytochrome b5 at a molar
ratio of CYP1A1:cytochrome b5 of 1:5. NADPH or NADH,
cofactors of POR, and NADH:cytochrome b5 reductase,
respectively, were utilised to examine CYP1A1-mediated
BaP oxidation. BaP metabolites formed by human
CYP1A1 in these enzyme systems were analysed by HPLC
(Fig. 4).
We show here results from our previous work [4] with
Supersomes (Figs. 4a, 5a) to be able to compare them to
our new results in Bactosomes. Seven BaP metabolites
were generated by human CYP1A1 in Supersomes both in
the presence of NADPH and NADH (Figs. 4a, 5a). They
were structurally identified previously [19, 20, 29] as BaP-
9,10-dihydrodiol (M1), BaP-7,8-dihydrodiol (M3), BaP-
1,6-dione (M4), BaP-3,6-dione (M5), BaP-9-ol (M6), and
BaP-3-ol (M7) (for structures, see Fig. 4d). In addition, a
metabolite of unknown structure (Mx) was detected. BaP-
Fig. 2 Electon transport
pathways to CYPs in the
endoplasmatic reticulum
(adopted from [32])
Comparison of human cytochrome P450 1A1-catalysed oxidation of benzo[a]pyrene in prokaryotic…
123
4,5-dihydrodiol (M2), which is a BaP metabolite generated
by rat CYP1A1 [19, 28], has not been detected in the
Supersome system with human CYP1A1. The metabolites
found in this CYP1A1 system indicated that BaP is meta-
bolised not only by CYP1A1 but also by EH, which is
important for the hydration of BaP-epoxides to produce
dihydrodiols. NADH was less effective than NADPH as
electron donor to human CYP1A1 in Supersomes (Fig. 5a).
The addition of cytochrome b5 to the incubation mixtures
with Supersomes at a molar ratio of CYP1A1 to cyto-
chrome b5 of 1:5 led to an increase in CYP1A1-mediated
BaP oxidation both in the presence of NADPH and NADH
(Fig. 5a). The highest stimulation effect of cytochrome b5
was seen on the generation of BaP-7,8-dihydrodiol in the
presence of NADPH or NADH as well as on the formation
of BaP-9,10-dihydrodiol, metabolite Mx, and BaP-3-ol in
the presence of NADH (Fig. 5a). No BaP metabolites were
found when NADPH or NADH was omitted from the
incubation mixtures containing CYP1A1-Supersomes
(Fig. 5a).
In the presence of NADPH, human recombinant
CYP1A1 expressed in Bactosomes was also capable of
oxidising BaP. However, only five BaP metabolites were
detectable in this system, namely, BaP-1,6-dione, BaP-3,6-
dione, BaP-9-ol, BaP-3-ol, and metabolite Mx, whereas no
BaP-dihydrodiols were detected (Figs. 4b, 5b). The same
BaP metabolites have been found previously in experi-
ments employing pure human recombinant CYP1A1
reconstituted with POR without any other enzymes (i.e.,
EH) in liposomes [4]. These results indicated that EH,
which catalyses the hydration of BaP-epoxides to dihy-
drodiols, even though expressed at low levels in
Bactosomes, is unable to produce BaP-dihydrodiols in
amounts detectable by HPLC. Except for BaP-1,6-dione
and BaP-3,6-dione, which were produced by the enzymes
in the prokaryotic system at levels similar to those formed
by CYP1A1 in Supersomes, the three other metabolites,
BaP-3-ol, BaP-9-ol, and metabolite Mx, were formed in
Bactosomes in significantly higher amounts than by the
CYP1A1-Supersome system (P\ 0.001 for BaP-9-ol and
BaP-3-ol and P\ 0.05 for Mx) (Fig. 5). 3.5-Fold higher
amounts of BaP-9-ol were formed in Bactosomes than
Supersomes, even though POR is expressed in Bactosomes
in lower levels than in Supersomes. Likewise, these three
BaP metabolites were formed more efficiently than BaP-
1,6-dione and BaP-3,6-dione in liposomes with CYP1A1
reconstituted with POR used in our previous work [4]. No
BaP metabolites were found when NADPH was omitted
from the incubation mixtures containing CYP1A1-Bacto-
somes (Figs. 4c, 5b).
NADH was ineffective as cofactor for BaP oxidation in
the CYP1A1-Bactosome system. This finding confirms that
NADH is a very poor coenzyme of POR over-expressed in
Bactosomes, leading to metabolite levels that are negligible
relative to NADPH. Recently, we found the same results
using cytochrome c as a substrate for POR [4, 5]. In con-
trast to the stimulating effect of cytochrome b5 on BaP
oxidation by human CYP1A1 in Supersomes, no such
effect was detected in the CYP1A1 system expressed in
E. coli (Fig. 5b). Even in the presence of the basal level of
NADH/cytochrome b5 reductase (Fig. 3) plus cytochrome
b5 with which the CYP1A1 in Bactosomes was
Fig. 3 Western blot analysis of CYP1A1, CYP1B1, POR, NADH:-
cytochrome b5 reductase (CBR) cytochrome b5 (b5), and epoxide
hydrolase (EH) in CYP1A1-Supersomes and CYP1A1-Bactosomes.
For Western blotting, 25 lg of protein was used for the analysis of
CYP1A1, CYP1B1, POR, CBR, and b5 and 50 lg of protein for the
analysis of EH. Representative blots are shown; analyses were
performed at least in duplicate
cFig. 4 HPLC chromatograms of BaP metabolites formed by human
recombinant CYP1A1 expressed in Supersomes (a) [4] and human
recombinant CYP1A1 expressed in a membrane of E. coli (Bacto-
somes) (b) in the presence of NADPH. c Control incubation mixture
containing BaP and bactosomes but no NADPH. d Structures of BaP
metabolites (M1, M3–M7, and Mx). PA phenacetin
M. Stiborova´ et al.
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reconstituted at a ratio of 1:5 (Fig. 5b), no effect of NADH
was detectable. However, after the reconstitution of Bac-
tosomes with NADH:cytochrome b5 reductase and
cytochrome b5 (at a ratio of CYP1A1:NADH:cytochrome
b5 reductase:cytochrome b5 of 1:1:5), these oxidized BaP
in the presence of NADH (Fig. 5c). These results con-
firmed the previous findings that the NADH/cytochrome b5
reductase/cytochrome b5 system can function as a sole
electron donor for CYP1A1 in its catalytic cycle, acting
independently of NADPH and POR [4, 5]. Nevertheless,
the levels of BaP metabolites generated in CYP1A1-Bac-
tosomes reconstituted with NADH:cytochrome b5
reductase and cytochrome b5 were much lower than their
levels generated by human CYP1A1 reconstituted with
these enzymes in liposomes [4].
Differences in membrane composition of the used
CYP1A1 systems, therefore, seem to play an essential role
in enzyme activity. This is described in a review by Sch-
neiter and Toulmay [46] who emphasise that the lipid
composition not only determines the sorting, orientation,
Fig. 5 Metabolism of BaP by human recombinant CYP1A1 in
Supersomes (a) [4] and Bactosomes b, c in the presence of either
NADPH or NADH and the effect of cytochrome b5 (at a molar ratio
of CYP1A1:cytochrome b5 of 1:5) (a, b) or NADH:cytochrome b5
reductase (CBR) (at a molar ratio of CYP1A1:CBR of 1:1) (c) on this
metabolism. BaP metabolites were measured by HPLC analysis.
Supersomes and Bactosomes containing basal levels of NADH:cy-
tochrome b5 reductase and cytochrome b5 were reconstituted with
additional cytochrome b5 (at a molar ratio of CYP1A1:cytochrome b5
of 1:5). Bactosomes shown in (C) were reconstituted with additional
NADH:cytochrome b5 reductase (CBR) and cytochrome b5 (CYP1A1
plus CBR plus cyt b5) at a molar ratio of CYP1A1:CBR:cyt b5 of
1:1:5). Values represent mean ± SD from three parallel measure-
ments. ND not detected. ***P\ 0.001 (Student’s t test), significantly
different from incubations using NADPH as cofactor (a);
DDDP\ 0.001 (Student’s t test), significantly different from incuba-
tions without cytochrome b5 (a);
###P\ 0.001 (Student’s t test),
significantly different from incubations in Bactosomes with NADPH
or NADH without CBR (c)
M. Stiborova´ et al.
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and assembly into oligomeric complexes of integral
membrane proteins but as a consequence also affects the
activity of membrane proteins. This is particularly true for
heterologous expression systems as in our case, where both
systems are heterologous; however, CYP1A1 and POR
expressed in the Supersomes seem to mimic the mam-
malian system more truly than the Bactosome system. The
pattern of BaP metabolites is shifted in the latter system
and the overall yield is not smaller but at least comparable
to Supersomes. In addition to the expressed enzymes, the
lipids of the membranes probably define functional uptake
of added membrane proteins in the reconstitution experi-
ments. In a highly artificial environment with liposomes
consisting of dilauryl-phosphatidylcholine and CHAPS,
cytochrome b5 also enhanced BaP oxidation by human
CYP1A1 [4].
Formation of BaP-DNA adducts by human CYP1A1
expressed in Supersomes and Bactosomes
in the presence of NADPH or NADH
We further compared the formation of BaP-DNA adducts
by human CYP1A1 expressed in Supersomes and Bacto-
somes using the 32P-postlabelling assay.
In our previous work up, two DNA adducts (assigned
adducts 1 and 2; see inserts in Fig. 6) were detected by 32P-
postlabelling when BaP was activated with human
CYP1A1 expressed in Supersomes in the presence of either
NADPH or NADH [4]. In this system, BaP-DNA adduct 1
was predominant (Fig. 6a) [4]. Comparison with the pre-
vious 32P-postlabelling analyses [19, 47] showed that
adduct 1 is the dG-N2-BPDE adduct. The other adduct, a
very minor DNA adduct in Supersomes, has similar chro-
matographic properties on thin-layer chromatography to a
guanine adduct derived from the reaction with 9-hydroxy-
BaP-4,5-epoxide (see adduct spot 2 in insert of Fig. 6). The
structure of this adduct has not yet been identified. No such
BaP-DNA adducts were found when NADPH or NADH
was omitted from the incubation mixtures (Fig. 6a).
Surprisingly, in the presence of NADPH, human
recombinant CYP1A1 over-expressed with POR in E. coli
bFig. 6 DNA adduct formation by BaP, measured by 32P-postla-
belling, activated with human recombinant CYP1A1 in Supersomes
(a) [4] and Bactosomes b, c in the presence of NADPH or NADH and
the effect of cytochrome b5 (cyt b5, at a molar ratio of CYP1A1:-
cytochrome b5 of 1:5) on this reaction. Bactosomes shown in (c) were
reconstituted with NADH:cytochrome b5 reductase (CBR) (CYP1A1
plus CBR) at a molar ratio of CYP1A1:CBR of 1:1. Insert A and B:
Autoradiographic profiles of BaP-DNA adducts formed by human
CYP1A1 in Supersomes and in Bactosomes in the presence of
NADPH and cytochrome b5, respectively, as evaluated by thin-layer
chromatography 32P-postlabelling as described previously [19].
Values represent mean total RAL (relative adduct labelling) ± SD
(n = 3; analyses of three independent in vitro incubations). ND, not
detected. ***P\ 0.001 (Student’s t test), levels of BaP-adduct 1
formed by incubations with CYP1A1 in Supersomes significantly
different from incubations with this enzymatic system without
cytochrome b5 (A);
DDDP\ 0.001 (Student’s t test), levels of BaP-
adducts 1 and 2 formed by incubations with CYP1A1 in Bactosomes
significantly different from incubations with this CYP1A1-Bacto-
somes system without CBR and cytochrome b5 (b, c)
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also generated BaP-DNA adducts 1 and 2 (Fig. 6), even
though BaP-7,8-dihydrodiol, the precursor of BPDE, was
not detectable by HPLC (Fig. 5b). This finding indicates
that EH expressed in Bactosomes even at very low levels is
capable of catalysing the hydration of BaP-7,8-epoxide to
BaP-7,8-dihydrodiol. It appears that the very low amounts
of BaP-7,8-dihydrodiol, undetectable by HPLC, generated
BPDE to form dG-N2-BPDE adducts detectable by the
highly sensitive 32P-postlabelling method (Fig. 6). This
suggestion is strongly supported by the previous results
showing that the 32P-postlabelling method used to detect
and quantify BaP-DNA adducts is up to six orders of
magnitude more sensitive than HPLC [48]. Levels of the
dG-N2-BPDE adduct (adduct 1) formed by CYP1A1 in
Bactosomes in the presence of NADPH were 1.6-fold
lower than those in Supersomes in the presence of this
cofactor (Fig. 6). The formation of adduct 2 by CYP1A1
expressed in Bactosomes was much higher than those
formed in the CYP1A1-Supersomes. These results corre-
sponded to higher amounts of BaP-9-ol formed in the
CYP1A1-Bactosome system than in CYP1A1-Supersomes
(BaP-9-ol is the precursor of 9-hydroxy-BaP-4,5-epoxide
generating adduct 2) (Figs. 5, 6).
Both cytochrome b5 and NADH:cytochrome b5 reduc-
tase enhanced formation of adduct 1 (i.e., dG-N2-BPDE) in
reconstituted systems containing Bactosomes and NADPH
(Fig. 6b, c). When NADH:cytochrome b5 reductase (at a
ratio of CYP1A1:NADH:cytochrome b5 reductase of 1:1)
plus cytochrome b5 (at a ratio of CYP1A1:cytochrome b5
of 1:5) were added together, levels of both BaP-DNA
adducts were lower than with only cytochrome b5 added to
the Bactosomes or in CYP1A1 Bactosomes alone. It is
possible that the higher amounts of protein in the incuba-
tion mixtures might scavenge the reactive BaP metabolites,
thereby decreasing BaP-DNA adduct formation. No BaP-
DNA adducts were found when NADPH was omitted from
the incubation mixtures containing human recombinant
CYP1A1 in Bactosomes (Fig. 6b, c).
NADH was ineffective as cofactor for BaP activation by
CYP1A1-Bactosomes (Fig. 6b, c), which again indicates
that NADH:cytochrome b5 reductase and/or its substrate
cytochrome b5 are not expressed in the membrane of
E. coli in states appropriate for catalysis. Furthermore,
these findings again indicate that NADH is a poor coen-
zyme of POR, over-expressed in Bactosomes. Only after
the reconstitution of Bactosomes with NADH:cytochrome
b5 reductase (at a ratio of CYP1A1: NADH:cytochrome b5
reductase of 1:1) plus cytochrome b5 (at a ratio of
CYP1A1:cytochrome b5 of 1:5), these were able to mediate
the formation of both BaP-DNA adducts in the presence of
NADH (Fig. 6c). These results again confirmed the pre-
vious findings that the NADH/cytochrome b5
reductase/cytochrome b5 system can act as an exclusive
electron donor for CYP1A1 in its catalytic cycle, func-
tioning independently of NADPH and POR [4, 5].
Nevertheless, the levels of BaP-DNA adducts formed in
Bactosomes reconstituted with NADH:cytochrome b5
reductase and cytochrome b5 were much lower than their
levels generated by human CYP1A1 reconstituted with
these enzymes in liposomes [4]. Here, again, the lipid
composition affects the yield in DNA adducts.
Conclusions
This study comparing two model systems containing
human recombinant CYP1A1 either expressed in eukary-
otic or prokaryotic cells (Supersomes or Bactosomes)
demonstrates different efficiencies of these systems in BaP
oxidation and the formation of BaP-derived DNA adducts.
Even though the human CYP1A1 enzyme essential for BaP
metabolism is over-expressed in both systems at similar
levels, its effectiveness in BaP oxidation differed signifi-
cantly. Our results strongly suggest that the lipid
composition of the membranes of these subcellular systems
is important for the yield of BaP metabolites and their
pattern. This might be an explanation for the discrepancies
in BaP metabolism observed by us and others from native
systems such as hepatocytes to heterologous expression
systems. This work also confirmed that expression systems
using eukaryotic cells such as Supersomes most closely
resemble the situation in human hepatic microsomes
[4, 29]. All BaP metabolites formed by Supersomes were
also formed by CYP1A1 in human hepatic microsomes and
human bronchoalveolar H358 cells (expressing CYP1A1)
after BaP exposure [15]. These results demonstrate that
NADH:cytochrome b5 reductase, cytochrome b5, and
epoxide hydrolase were necessary to transform BaP to
these metabolites, although expressed at low levels in the
‘‘supersomal’’ microsomes seems to be in functional states
and as active as in human cells.
Experimental
Chemicals and CYP1A1 subcellular systems
BaP (CAS no. 50-32-8; purity C96%), NADH (as dis-
odium salt; purity *95%), and NADPH (as tetrasodium
salt; *98% purity) were obtained from Sigma Chemical
Co (St Louis, MO, USA). CYP1A1-Supersomes, micro-
somes isolated from insect cells transfected with a
baculovirus construct containing cDNA of human
CYP1A1 and POR that are therefore over-expressed in
these microsomes, were purchased from Gentest Corp.
(Woburn, MI, USA). However, because they are
M. Stiborova´ et al.
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microsomes, other enzymes (proteins) of the endoplasmic
reticulum membrane (i.e., NADH:cytochrome b5 reduc-
tase, EH, and cytochrome b5) are also expressed at basal
levels in these SupersomesTM (Gentest Corp., Woburn,
MI, USA). Bactosomes, a membrane fraction isolated
from cells of E. coli transfected with construct of cDNA
of human CYP1A1 and human POR and, therefore, over-
expressed in these Bactosomes, were obtained from
Cypex (BioDundee, Dundee, UK). Supersomes and Bac-
tosomes were isolated from insect and E. coli cells,
respectively, that were not transfected with NADH:cy-
tochrome b5 reductase or cytochrome b5.
Western Blot analysis
For the detection of CYP1A1, 1B1, EH, POR, NADH:cy-
tochrome b5 reductase, and cytochrome b5 in CYP1A1-
Supersomes and CYP1A1-Bactosomes, 25 lg or 50 lg
(for EH) of protein were subjected to sodium dodecylsul-
fate polyacrylamide gel electrophoresis (SDS-PAGE)
(4–20% Mini-PROTEAN TGXTM Gel 15 well, Bio-Rad)
and applied onto a polyvinylidene fluoride (PVDF) mem-
brane (Trans-Blot TurboTM Mini PVDF Transfer Packs,
Bio-Rad) as reported [11, 49]. The membrane was blocked
in 5% (w/v) non-fat milk dissolved in PBS-Triton X-100
buffer [0.134 M NaCl, 1.8 mM Na2HPO4, 1 mM NaH2-
PO4; pH 7.2; 0.3% (w/v) Triton X-100] for 1 h at ambient
temperature, then probed overnight at 4 C with the fol-
lowing antibodies: human CYP1A1 was detected with a
goat anti-rat CYP1A1 antibody (1:1250, Antibodies-online
GmbH, Aachen, Germany), CYP1B1 with rabbit-anti-hu-
man CYP1B1 polyclonal antibody (G-25) (1:200, Santa
Cruz Biotechnology, Dallas, Texas, USA), POR with rab-
bit-anti-human cytochrome P450 reductase polyclonal
antibody (1:500, AbCam, MA, USA), NADH:cytochrome
b5 reductase with goat anti-rat cytochrome b5 reductase 3
antibody (CYB5R3, C-Term; 1:1000, Antibodies-online
GmbH, Aachen, Germany), EH with rabbit anti-human
epoxide hydrolase polyclonal antibody (1:1000, AbCam,
MA, USA), and cytochrome b5 with a rabbit anti-human
cytochrome b5 polyclonal antibody (1:750, AbCam, MA,
USA) diluted in 5% non-fat milk in PBS-buffered saline
with Triton X-100 (PBS-Triton buffer). After washing in
PBS-Triton, the antigen–antibody complexes were visu-
alised with either alkaline phosphatase-conjugated goat
anti-rabbit IgG antibody (1:1428, Sigma-Aldrich, USA) or
chicken anti-goat IgG antibody (1:500, Santa Cruz
Biotechnology, Dallas, Texas, USA), and 5-bromo-4-
chloro-3-indolylphosphate/nitrobluetetrazolium (BCIP/
NBT Color Development Substrate, Promega WI, USA)
was used as chromogenic substrate. Antibody against
glyceraldehyde phosphate dehydrogenase (GAPDH)
(1:750, Millipore, Massachusetts, USA) was used as
loading control as recommended by the manufacturer (not
shown).
Isolation of Rat NADH:cytochrome b5 reductase
and rabbit cytochrome b5
Cytochrome b5 reductase (E.C. 1.6.2.2) was isolated from
rat liver microsomes by a procedure described by Perkins
and Duncan [51]. The specific activity of rat cytochrome b5
reductase measured as NADH-ferricyanide reductase was
49.2 lmol ferricyanide/min/mg protein. Cytochrome b5
was isolated from rabbit liver microsomes as described
[52]. Both proteins purified to apparent homogeneity
[51, 52] were utilised in the reconstitution experiments
with Bactosomes (cytochrome b5 and NADH:cytochrome
b5 reductase) and Supersomes (cytochrome b5).
Incubations to study metabolism of BaP by human
recombinant CYP1A1 in Supersomes or Bactosomes
Incubation mixtures used for studying BaP metabolism by
Supersomes or Bactosomes contained in a final volume of
0.25 cm3 100 mmol dm-3 potassium phosphate buffer (pH
7.4), 1 mmol dm-3 NADPH or NADH, 50 lmol dm-3
BaP (dissolved in 0.025 cm3 DMSO). With this DMSO
concentration (1% as a final concentration), no inhibition of
the NADPH-dependent CYP-catalysed oxidation of several
substrates has been found previously
[4–6, 9, 10, 19, 28, 29, 35] and 100 nmol dm-3 human
recombinant CYP1A1 present with its reductase, POR, in
Supersomes or Bactosomes. Control incubations contained
no NADPH. The same amount of a solvent (DMSO) was
used in control incubations without BaP. The reaction was
initiated by adding NADPH or NADH. In the experiments,
where the effect of cytochrome b5 on BaP metabolism by
human CYP1A1 in Supersomes or Bactosomes was
investigated, 500 nmol dm-3 of pure cytochrome b5 pro-
tein was added to reach a molar ratio of
CYP1A1:cytochrome b5 of 1:5 and reconstituted with
Supersomes or Bactosomes (see Figs. 5, 6). CYP1A1
enzyme (100 nmol dm-3) reconstitution utilizing Super-
somes or Bactosomes with purified cytochrome b5
(500 nmol dm-3) was performed as described elsewhere
[4–6, 9, 10, 19, 20, 28, 29, 35, 36, 49, 50]. Negative con-
trols lacked either CYP1A systems or cofactors. After
incubation (37 C, 20 min), 0.005 cm3 1 mmol dm-3
phenacetin in methanol was added as an internal standard.
BaP metabolism by microsomes has been shown to be
linear up to 30 min of incubation [4, 5, 19, 20]. BaP
metabolites were extracted twice with ethyl acetate
(2 9 1 cm3), solvent evaporated to dryness, residues dis-
solved in 0.025 cm3 methanol, and BaP metabolites
separated by HPLC as reported previously [4, 5, 19, 20].
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BaP metabolite peaks were identified by HPLC by com-
parison with metabolite standards, whose structures were
determined previously by NMR and/or mass spectrometry
[19].
Determination of BaP-DNA adduct formation
by 32P-postlabelling
Incubation mixtures used to assess DNA adduct formation
by BaP activated with all enzymatic systems containing
human CYP1A1 consisted of 50 mmol dm-3 potassium
phosphate buffer (pH 7.4), 1 mmol dm-3 NADPH or
NADH, 100 nmol dm-3 human recombinant CYP1A1 in
Supersomes and reconstituted with 500 nmol dm-3 cyto-
chrome b5 (at a ratio of CYP1A1:cytochrome b5 of 1:5) or
in Bactosomes and reconstituted with 100 nmol dm-3
NADH:cytochrome b5 reductase and 500 nmol dm
-3
cytochrome b5 as indicated in the figures, 0.1 mmol dm
-3
BaP (dissolved in 0.0075 cm3 DMSO), and 0.5 mg of calf
thymus DNA in a final volume of 0.75 cm3 as described
previously [4, 19]. The reaction was initiated by adding
0.1 mmol dm-3 BaP and incubations were carried out at
37 C for 60 min. BaP-DNA adduct formation has been
shown to be linear up to 90 min [10, 19]. Control incu-
bations were carried out either without CYP1A1 in
Supersomes and in Bactosomes, without NADPH (or
NADH), without DNA, or without BaP. After the incuba-
tion, BaP and metabolites were extracted with ethyl acetate
and DNA was isolated from the residual water phase by the
standard phenol/chloroform extraction. DNA adduct for-
mation was analysed using the nuclease P1 version of the
32P-postlabelling technique [4, 5, 10, 19]. Resolution of the
adducts by thin-layer chromatography using polyethylen-
imine-cellulose plates (Macherey and Nagel, Du¨ren,
Germany) was carried out as described [4, 5, 10, 19, 48].
DNA adduct levels (RAL, relative adduct labelling) were
calculated as described [54]. As mentioned above, since
Bactosomes contain very low levels of NADH/cytochrome
b5 reductase according to the provider, we added this
enzyme to the reconstituted system with Bactosomes
(100 nmol dm-3), at a ratio of CYP1A1:NADH:cy-
tochrome b5 reductase of 1:1).
Statistical analyses
Statistical analyses were carried out with Student’s t test
(Unistat Ltd, Highgate, London N6 5UQ, ENGLAND UK).
Means ± standard deviations of three parallel experiments
are shown and P values\0.05 were considered significant.
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